García-Álvarez, María
Alonso-Álvarez, Sara
Prieto-Conde, Isabel http://orcid.org/0000-0002-2510-8355
Jiménez, Cristina
Sarasquete, M. Eugenia http://orcid.org/0000-0001-7335-3657
Chillón, M. Carmen
Medina, Alejandro http://orcid.org/0000-0001-5609-2969
Balanzategui, Ana
Maldonado, Rebeca
Antón, Alicia
Rodríguez, Marta
Blanco, Oscar
Díaz, Luis G.
Tamayo, Pilar
Blanco, Pedro
Esteban, Carmen
González-Calle, Verónica
Puig, Noemí
Gutiérrez, Norma
Martín, Alejandro
García-Sanz, Ramón http://orcid.org/0000-0003-4120-2787
González, Marcos
Caballero, M. Dolores
Alcoceba, Miguel http://orcid.org/0000-0002-3819-4846
Funding for this research was provided by:
Cancer Research UK (AAC - Accelerator Award Full)
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (CD19/00030, CPII18/00028, FI19/00320, CIBERONC-CB16/12/00233, PI15/01390, PI18/00410)
Fundación Científica Asociación Española Contra el Cáncer (PROYE18020BEA)
Ministry of Economy and Competitiveness | Secretaría de Estado de Investigación, Desarrollo e Innovación (Innocampus; CEI-2010-1-0010)
Consejería de Educación, Junta de Castilla y León (CAS102P17)
Article History
Received: 25 August 2020
Revised: 19 November 2020
Accepted: 27 November 2020
First Online: 11 January 2021
Conflict of interest
: The authors report grants PI15/01393, PI18/00410, CAS102P17, GRS1180/A/15, GLD17/00334, CIBERONC-CB16/12/00233, PROYE18020BEA during the conduct of the study, and from Gilead Sciences (GLD15/00348, GLD16/00162, GLD18/00117), Incyte, Janssen, Celgene, and Amgen outside the submitted work. M.G.A., I.P.C., C.J., M.E.S., A.Me., and V.G.C. are or were supported by the Spanish government (ISCIII and/or FEHH). Consulting fees and/or non-financial support were reported from Abbvie (M.G., M.A., M.D.C.), Amgen (N.P., M.D.C.), Binding Site (N.P.), Bristol-Myers Squibb (V.G.C., N.P., A.M., R.G.S., M.D.C.), Eusa Pharma (A.M.), Gilead (A.M., M.G., M.D.C.), iQone Healthcare (A.M.), Incyte (R.G.S.), Janssen (V.G.C., N.P., A.M., R.G.S., M.G., M.D.C., M.A.), Kite (M.D.C.), Kyowa Kirin (A.M.), MSD (M.D.C.), Novartis (S.A.A., M.D.C.), Prothena (V.G.C.), Roche (A.M., M.G., M.D.C., M.A.), Servier (A.M., M.D.C.), Takeda (N.P., R.G.S., M.D.C.), and Weber (N.P.). The remaining authors have no relevant conflicts of interest to disclose. R.G.S. is the president of the Spanish Society of Hematology.